
Youn Jae Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9026413/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. The Lancet Gastroenterology and Hepatology, 2018, 3, 37-46.	3.7	127
2	A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver International, 2013, 33, 586-594.	1.9	81
3	Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. Liver International, 2015, 35, 2246-2255.	1.9	66
4	Clinical and epidemiological features of hepatitis C virus infection in South Korea: A prospective, multicenter cohort study. Journal of Medical Virology, 2013, 85, 1724-1733.	2.5	65
5	Factors Associated with Health-Related Quality of Life in Korean Patients with Chronic Hepatitis C Infection Using the SF-36 and EQ-5D. Gut and Liver, 2018, 12, 440-448.	1.4	23
6	Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study. Gut and Liver, 2020, 14, 207-217.	1.4	18
7	Prospective cohort study on the outcomes of hepatitis <scp>C</scp> virusâ€related cirrhosis in <scp>S</scp> outh <scp>K</scp> orea. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1281-1287.	1.4	17
8	Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study. Journal of Korean Medical Science, 2018, 33, e264.	1.1	13
9	Geographic differences in the epidemiological features of HCV infection in Korea. Clinical and Molecular Hepatology, 2014, 20, 361.	4.5	11
10	An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection. Clinical and Molecular Hepatology, 2019, 25, 400-407.	4.5	7
11	Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era. Gut and Liver, 2017, 11, 543-550.	1.4	7
12	Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose. Gut and Liver, 2020, 14, 775-782.	1.4	6
13	Role of Interleukin-28B Genetic Polymorphisms in Korean Patients with Hepatitis C Virus Infection. Gut and Liver, 2014, 8, 70-78.	1.4	6
14	Baracle [®] vs Baraclude [®] for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety. Drug Design, Development and Therapy, 2017, Volume 11, 3145-3152.	2.0	5
15	Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study. Korean Journal of Internal Medicine, 2021, 36, S1-S8.	0.7	4
16	Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea. Clinical and Molecular Hepatology, 2015, 21, 125.	4.5	4
17	Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. Gut and Liver, 2021, 15, 895-903.	1.4	3
18	The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80Â% full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. Hepatology International, 2013, 7, 1000-1009.	1.9	2

#	Article	IF	CITATIONS
19	Pre-stimulation of CD81 expression by resting B cells increases proliferation following EBV infection, but the overexpression of CD81 induces the apoptosis of EBV-transformed B cells. International Journal of Molecular Medicine, 2015, 36, 1464-1478.	1.8	2
20	Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in South Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID. Epidemiology and Health, 2021, , e2021077.	0.8	2
21	Realâ€life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistanceâ€associated substitution test. Journal of Medical Virology, 2019, 91, 2158-2165.	2.5	1
22	Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. Drug Design, Development and Therapy, 2018, Volume 12, 3767-3774.	2.0	0